Canakinumab (Subcutaneous Route)
Name: Canakinumab (Subcutaneous Route)
- Canakinumab Subcutaneous Route brand name
- Canakinumab Subcutaneous Route dosage
- Canakinumab Subcutaneous Route dosage forms
- Canakinumab Subcutaneous Route injection
- Canakinumab Subcutaneous Route used to treat
- Canakinumab Subcutaneous Route treats
- Canakinumab Subcutaneous Route is used to treat
- Canakinumab Subcutaneous Route effects of
- Canakinumab Subcutaneous Route the effects of
US Brand Name
- Ilaris
Descriptions
Canakinumab injection is used to treat cryopyrin-associated periodic syndromes (CAPS). This also includes familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). CAPS is a rare, inherited disease of the immune system. It occurs when the body produces too much of a chemical called interleukin-1 beta. This chemical causes inflammation, and patients with CAPS may have a fever, headache, skin rash, joint or muscle pain, or unusual tiredness or weakness.
Canakinumab helps prevent inflammation by keeping the interleukin-1 beta from working properly. This medicine also treats adults and children with other autoinflammatory periodic fever syndromes, such as tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF).
Canakinumab is also used to treat active systemic juvenile idiopathic arthritis (SJIA) in children 2 years of age and older.
This medicine is to be given only by or under the direct supervision of a doctor.
This product is available in the following dosage forms:
- Powder for Solution
Geriatric
Appropriate studies on the relationship of age to the effects of canakinumab injection have not been performed in the geriatric population. However, no geriatric-specific problems have been documented to date.